therosclerosis, the underlying cause of coronary heart disease, is essentially a complex inflammatoryfibroproliferative response of the arterial wall. Atherogenic processes include vascular injury, infiltration of monocytes/ macrophages, lipid accumulation, phenotypic alteration of smooth muscle cells (SMC), and reorganization of extracellular matrix (ECM). 1, 2 Although the arterial wall is composed to a large extent of SMC and their ECM products, endothelial cells (EC), infiltrating cells, and adventitial fibroblasts each represent only a small proportion of cells occurring in the vessel wall. 3 Ninety percent of the total protein in the atherosclerotic plaque consists of collagens, ie, type I and type III collagen. 4, 5 Other members of the collagen family, type IV and type V collagen, probably play important roles in the processes of SMC phenotype modulation, vascular repair, and plaque stabilization. 6, 7 It is becoming increasingly clear that type VIII collagen is a key structural component of the vasculature. Type VIII collagen belongs to the group of short-chain collagens and forms 3-dimensional networks. 8 The homology of type VIII collagen to type X collagen has been described. 9 Type VIII collagen has been localized to the tunica media and tunica intima of elastic arteries. 10, 11 Its expression by the constituent cell types of the arterial wall, ie, SMC and EC, has been reported. 12, 13 In the rat balloon injury model it has been demonstrated to be an important component of the SMC response to injury and has been suggested to play a functional role in mediating migration of SMC. 14 Type VIII collagen is markedly expressed in atherosclerotic arteries. 15 Atherogenic processes are modulated by cytokines and growth factors, which are synthesized and released by the constituent cell types of the vessel wall. 16, 17 SMC have been shown to be capable of producing a number of cell mediators such as inflammatory cytokines, eg, colony-stimulating factors (CSF), 16 and growth factors involved in ECM remodeling, eg, basic fibroblast growth factor (bFGF), 4 plateletderived growth factor (PDGF), 18 and transforming growth factor-␤1 (TGF-␤1), 4 which interact with mediators produced by the other vascular cell types.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been increasingly implicated as a critical player in atherogenesis. 19 GM-CSF is a glycoprotein cytokine first characterized for its ability to stimulate progenitor hematopoietic cells to proliferate and differentiate into mature granulocytes and macrophages. 20, 21 Subsequently it has been shown to have multiple effects in immune activation and in stimulating proliferation, 22, 23 acting in concert with other members of the CSF family as a key mediator in inflammation and host defense. 24, 25 Although CSF, including GM-CSF, are rapidly synthesized by a variety of cell types in response to injury, the ensuing accumulation of monocytes/macrophages and T lymphocytes in the tissue constitutes the hallmark of the inflammatory response. 23, 26, 27 It has been shown previously that type VIII collagen and GM-CSF are strongly expressed in atherosclerotic lesions. 15, 19 Apparent similarities in the distribution patterns of these molecules were observed. However, attempts to evaluate their potential codistribution and association have not been made.
This study is an in situ hybridization, immunohistochemical, and molecular biological assessment of the temporal and spatial distribution of GM-CSF and type VIII collagen in the nondiseased arterial wall and during the development of atherosclerotic lesions in human coronary arteries. Furthermore, we studied the effects of GM-CSF on the expression of type VIII collagen mRNA in cultured SMC. Our results demonstrate that GM-CSF and type VIII collagen are codistributed in the arterial wall and provide evidence that GM-CSF might play a part in regulating remodeling of the ECM during atherogenesis.
Methods

Patients, Samples, and Tissue Preparation
Human coronary artery specimens and aortic tissue samples were obtained from explanted hearts of patients undergoing cardiac transplantation and from tissue obtained during cardiac surgery as detailed in Table 1 . The protocol was approved by the local ethics Figure 1 . Coexpression of GM-CSF and type VIII collagen mRNA in EC and SMC. Simultaneous in situ hybridization (black stain) and immunohistochemistry (red stain) shows the occurrence of both GM-CSF and type VIII collagen mRNA in EC (A) and in SMC (B). EC were identified using rabbit antihuman von Willebrand factor and SMC using mouse anti-human ␣/␥ actin (HHF35). Bright field; magnification ϫ200 (A); ϫ100 (B). RT-PCR analyses showing the expression of GM-CSF and type VIII collagen mRNA in cultivated human umbilical vein EC (A') and in SMC (B'). GM-CSF and type VIII collagen mRNA are basally expressed by EC and SMC. e indicates endothelium; i, intima; li, lamina elastica interna; m, media; GM, GM-CSF mRNA; CVIII, ␣1(VIII) collagen mRNA; and M, DNA marker, pUC19, digested with HinfI. 
Cell Culture
Human SMC (nϭ4) were isolated and cultured as previously described 19 or obtained from BioWhittaker Inc. In brief, endothelium was removed enzymatically from aortic tissue, and SMC were subsequently released by enzymatic digestion. The cells were cultured in Dulbecco's modified Eagle's medium with 20% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and 4 mmol/L L-glutamine. To evaluate the effect of GM-CSF on the transcription of ␣1(VIII) procollagen mRNA, cell culture experiments were performed as follows: SMC were cultured to subconfluence and then preincubated for 48 hours with Dulbecco's modified Eagle's medium with 0.5% FBS. Preincubation was followed by incubation with Dulbecco's modified Eagle's medium with 0.5% FBS containing GM-CSF (1.0, 10, 100, and 500 pg/mL; Genzyme) for 35 minutes, 2 hours, 4 hours, and 24 hours. After incubation, cells were washed twice in PBS and then lysed directly in the culture flasks by adding 4 mL guanidinium isothiocyanate solution.
Peripheral blood monocytes were isolated from volunteer donors (nϭ3) by monocytapheresis, followed by elutriation and countercurrent centrifugation as previously described, 30 and maintained in RPMI-1640 medium supplemented with 20% pooled human serum, 1 mmol/L sodium pyruvate, 20 mmol/L glutamine, and 1ϫ essential amino acids (Gibco). Total RNA was isolated after 7 days and 14 days cultivation and 14 days cultivation followed by stimulation with lipopolysaccharide (LPS; 10 and 100 ng/mL) for 24 hours.
Human umbilical vein EC (nϭ3) were isolated from umbilical cords and cultured as described elsewhere. 31, 32 For RNA isolation, confluent monolayers were lysed directly in the culture flasks. Until isolation of total RNA, all RNA lysates were stored at Ϫ20°C.
The purity of SMC and EC cultures was verified by immunohistochemistry using SMC and EC type-specific antibodies. Monocytes were differentiated from macrophages by immunohistochemistry and type-specific monoclonal antibodies.
Labeling Procedure and Northern Blot Analysis
For hybridization, the recombinant cDNA clones, phGM-CSF, 19 containing an insert complementary to the human GM-CSF mRNA (R&D Systems), pBSIIa1Col8, complementary to human procollagen ␣1(VIII), and G3PDH (Clontech), complementary to human glyceraldehyde-3-phosphate dehydrogenase mRNA, were used. In vitro transcription was performed according to the manufacturer's protocol with modifications using digoxigenin-labeled UTP (Boehringer Mannheim).
Total RNA was isolated from human umbilical vein EC, SMC, and human monocytes/macrophages according to Chirgwin et al. 33 Northern blot analysis was performed as previously described 19 overnight at 72°C. Detection was performed using a modified protocol (Boehringer Mannheim) and the chemiluminogenic substrate 3-(4-methoxispiro{1,2-dioxetan-3,2Ј-(5Ј chloro)tricyclo[3.3.1.1 3, 7 ]-decan}-4-yl) phenylphosphate.
To evaluate the relative expression, the luminographs on x-ray film were scanned using a laser densitometer (Personal Densitometer, Molecular Dynamics). Densitometric values of procollagen ␣1(VIII) mRNA expression were corrected for G3PDH mRNA values. Corrected values were normalized against the level of expression determined at 48 hours of preincubation. Relative expression was expressed in mean values (nϭ4) ϮSD. Differences were assessed by Student's t test. Probability values Ͻ0.05 were considered significant.
Reverse Transcription-Polymerase Chain Reaction
One microgram of total RNA from SMC, human monocytes/macrophages, and human umbilical vein EC was reverse transcribed (RT) using Superscript II RNase H Ϫ according to the manufacturer's instructions (Gibco BRL; Life Technologies GmbH). The PCR amplification of the GM-CSF product was performed as previously described. 19 The upstream and downstream PCR primers for GM-CSF (DNA accession No. X03021, GenBank) 5Ј-GCAAGCTTCTGTACAAGCAGGGCCTG-3Ј (sequence location 1673 to 1690) and 5Ј-GCTCTAGATCCCAGCAGTCAAA-GGGG-3Ј (sequence location 2652 to 2669), product size 204 bp, were used.
For amplification of the ␣1(VIII) procollagen (DNA accession No. X57527, GenBank) product, the upstream and downstream primers 5Ј-AGCTGTGATGATGCCCCCTACACCA-3Ј (sequence location 2212 to 2235) and 5Ј-TTACATGGGATACAA-TAAATATCC-3Ј (sequence location 1713 to 1734), product size 522 bp, were used. RT products were amplified in a solution containing 3 mmol/L MgCl 2 , 0.1 mmol/L each of dNTP, 1ϫ buffer (20 mmol/L Tris-HCl, pH 8.4, 50 mmol/L KCl), 2.5 U of Taq polymerase (Gibco BRL), and 1 mol/L of each primer. Amplification was performed after initial denaturation at 95°C for 5 minutes for 35 cycles using the following temperature and time profile: denaturation at 95°C for 30 seconds, primer annealing at 62°C for 30 seconds, primer extension at 72°C for 30 seconds, and a final extension of 72°C for 15 minutes. Aliquots of the PCR reaction products were analyzed using standard agarose gel electrophoresis.
In Situ Hybridization
In situ hybridization was performed as described 19 either with 0.3 g/mL digoxigenin-labeled cRNA probe (antisense or sense strand of the GM-CSF and type VIII collagen cDNA) or with hybridization solution only at 52°C. Detection was done using the anti-digoxigenin alkaline phosphatase system according to the manufacturer's instructions (Boehringer Mannheim). The staining procedure was performed in the dark for 4 hours or overnight using nitroblue tetrazolium salt (NBT; 67.5 mg/mL; Biomol) and 5-bromo-4-chloro-3-indolyl phosphate (X-PO 4 ; 35 mg/mL; Biomol) as substrates. Sections were mounted with Kaiser's glycerin gelatin.
Immunohistochemical Identification of Cell Types
Cultured cell types were identified as follows: (1) for EC, rabbit anti-human von Willebrand factor (Sigma); (2) for SMC, mouse anti-human ␣/␥ actin (HHF35; Loxo); (3) for macrophages, mouse anti-human 25F9 (BMA); and (4) for monocytes, mouse anti-human heterocomplex MRP8-MRP14 (27E10; BMA) were used. As secondary antibody detection system we used donkey anti-mouse and donkey anti-rabbit immunoglobulin conjugated to Cy3 (Chemicon).
The alkaline phosphatase detection procedure for in situ hybridization was followed by immunohistochemical detection of (1) macrophages (mouse anti-human CD 68, clone PG-M1; Dako); (2) EC (rabbit anti-human von Willebrand factor); or (3) SMC (HHF35), using the POD Vectastain Elite kit according to the manufacturer's instructions (Serva). Type VIII collagen was localized by using mouse anti-bovine type VIII collagen (C8; Medac). As secondary antibodies, biotin-conjugated goat antirabbit IgG or horse anti-mouse IgG (Vector Laboratories) were used. The peroxidase staining procedure was performed as described. 19 Alternatively the immunofluorescence protocol was performed using as secondary antibody detection system donkey anti-mouse or donkey anti-rabbit immunoglobulin conjugated to Cy3 (Chemicon).
Results
GM-CSF and Type VIII Collagen Are Expressed by Different Cell Types of the Arterial Wall
We studied GM-CSF and type VIII collagen mRNAexpressing cell types using combined in situ hybridization and immunohistochemistry and in vitro RNA analyses. In the arterial wall both GM-CSF and type VIII collagen mRNA were expressed by EC, SMC ( Figure 1A and 1B) , and macrophages (Figure 2A and 2B) . However, not all cells stained by the respective markers also expressed GM-CSF or type VIII collagen mRNA.
The expression of GM-CSF and type VIII collagen mRNA was also studied in cultured EC, SMC, and macrophages. As demonstrated by RT-PCR, both mRNA were expressed basally in cultured EC ( Figure 1A' ) and SMC ( Figure 1B' ). Monocytes placed in culture expressed GM-CSF mRNA (Figure 2A' ) after 7 days of cultivation, but not after 14 days of cultivation when differentiated into macrophages. Cultivated monocytes developed into macrophages within 2 weeks of cultivation. Monocytes were differentiated from macrophages by staining with the monocyte marker 27E10 and the macrophage marker 25F9. However, in the 14-day-old monocyte-derived macrophages GM-CSF mRNA could be induced by endotoxin activation. In comparison, type VIII collagen mRNA was basally expressed both in monocytes and macrophages ( Figure 2B' ). Treatment with endotoxin did not markedly affect the level of type VIII collagen mRNA in 14-day-old monocyte-derived macrophages. Type VIII collagen accumulated extracellularly in directly adjacent areas (arrows). E and F, Negative controls for in situ hybridization (E) using digoxigenin-labeled cRNA coding for GM-CSF and for immunohistochemistry (F) without using the primary antibody. Magnification ϫ100 (A, B, E, and F); ϫ200 (C and D). Arrowheads indicate the internal elastic lamina; other abbreviations are as in Figures 1 and 3 .
Co-Occurrence of GM-CSF and Type VIII Collagen
The occurrence of GM-CSF mRNA and type VIII collagen protein in the same areas of atherosclerotic lesions was demonstrated using combined in situ hybridization and immunohistochemistry. In nondiseased arteries type VIII collagen was strongly expressed by EC, and faint and homogeneous staining was observed throughout the entire media (not shown). In early lesions (Figure 3) , exemplary shown for a type III lesion, type VIII collagen was predominantly located in the endothelium and the luminal aspect of the intima ( Figure 3A) . Some signal also occurred in other parts of the intima and in the media. The distribution pattern of type VIII collagen was directly reflected by the occurrence of GM-CSF Figure 5 . Localization of GM-CSF and type VIII collagen mRNA in the nondiseased artery wall and in early atherogenesis. In situ hybridization was with GM-CSF (A, C, and E) and ␣1(VIII) procollagen (B, D, and F) antisense riboprobes. In the nondiseased artery, cells expressing GM-CSF (A) and type VIII collagen (B) mRNA were localized in the endothelium and in the subendothelial region (arrows). In intimal thickenings (C and D) and early lesions (E and F), signals for GM-CSF and type VIII collagen mRNA were apparent in the endothelium, in the intima, and especially in the media. Arrows highlight selected areas of colocalization. Bright field; magnification ϫ100 (A, B, E, and F); ϫ40 (C and D). Arrowheads indicate internal and external elastic laminae; a, adventitia; other abbreviations are as in Figures 1 and 3 . D) are codistributed in the endothelium, subendothelial region, plaque core (highlighted for selected areas by arrows), and media (indicated by rhombi). However, not all regions showing strong expression of type VIII collagen mRMA were strongly labeled for GM-CSF (A and D). E, Negative control for in situ hybridization using digoxigeninlabeled cRNA coding for ␣1(VIII) procollagen and for immunohistochemistry without using the primary antibody. Bright field; magnification ϫ40 (A through E). Arrowheads indicate internal and external elastic laminae; other abbreviations are as in Figures 1 and 3.   Figure 7 . Co-occurrence of GM-CSF and type VIII collagen mRNA in the vasa vasorum. In situ hybridization was with GM-CSF (A) and ␣1(VIII) procollagen (B) antisense riboprobes and simultaneous immunohistochemistry using HHF35 (mouse anti-human ␣/␥-actin) as SMC marker (B). Cells expressing GM-CSF (A) and type VIII collagen (B) mRNA occurred in endothelium, media, and surrounding adventitial tissue. Bright field; magnification ϫ200 (A and B) . Arrowheads indicate internal and external elastic laminae; other abbreviations are as in Figures 1 and 3. mRNA-expressing cells ( Figure 3B ). In advanced, type V lesions, both GM-CSF mRNA and type VIII collagen are more widely distributed ( Figure 4A and 4B) . In areas adjacent to clusters of GM-CSF mRNA-expressing cells, type VIII collagen was more strongly deposited ( Figure 4C and 4D) .
Expression of GM-CSF and Type VIII Collagen in Nondiseased Arteries and During Early Atherogenesis
To follow the expression patterns of GM-CSF mRNA and type VIII collagen mRNA during atherogenesis, comparative in situ hybridizations were performed. Apparently nondiseased coronary artery segments consistently contained distinct GM-CSF ( Figure 5A ) and collagen type VIII mRNApositive cells ( Figure 5B ). Expression of both mRNAs was apparent in the endothelium and in cells that were irregularly scattered beneath the endothelium. Positive cells were occasionally observed throughout the entire media. However, the signals were lower and the major part of the media was devoid of label. Positively stained cells were also regularly found in the vessel lumen. Compared with type VIII collagen mRNA, fewer cells expressed GM-CSF mRNA. These patterns of expression were consistently observed in sections from all the patients examined.
In intimal thickenings (Figure 5C and 5D) and early atherosclerotic lesions ( Figure 5E and 5F), the extents and patterns of GM-CSF ( Figure 5C and 5E) and collagen type VIII ( Figure 5D and 5F) mRNA expression differed from those in the nondiseased vessels. In these early stages both GM-CSF and type VIII collagen mRNA were present in the endothelium, as shown before for nondiseased arteries, in the intima, and in the media. Positive cells were distributed throughout the entire medial layer. As already mentioned for the nondiseased arteries, the overall expression of GM-CSF mRNA was lower compared with that of type VIII collagen mRNA.
Expression of GM-CSF and Type VIII Collagen in Advanced (Types IV and V) and Complicated (Types VI through VIII) Atherosclerotic Lesions
The number of GM-CSF and type VIII collagen mRNAexpressing cells increased with further intimal thickening and was yet more prominent in advanced (types IV and V) atherosclerotic lesions (Table 2 ). Figure 6 shows the typical distribution patterns of type VIII collagen and GM-CSF mRNA in a type V lesion. Type VIII collagen ( Figure 6A ) and GM-CSF ( Figure 6B to 6D) mRNA-positive cells were Figure 8 . Expression of GM-CSF and type VIII collagen mRNA in a typical type VIII lesion revealed by in situ hybridization with GM-CSF (A and C) and ␣1(VIII) procollagen (B and D) antisense riboprobes. In general, type VIII collagen mRNA is more widely distributed than GM-CSF mRNA. GM-CSF-and ␣1(VIII) procollagen-expressing cells are codistributed only in the core and base of type VIII lesions, which are composed predominantly of monocytes/macrophages. Boxes indicate selected areas of co-occurrence. Bright field; magnification ϫ100 (A through D). Abbreviations are as in Figures 1 and 3. observed scattered throughout the entire thickened intima. Furthermore, a characteristic feature of this type of lesion was clustering of positive cells in large foci deep in the intima, particularly in the plaque core ( Figure 6B ), and in small groups immediately below the endothelium ( Figure 6C ). In addition, conspicuous signals were apparent over large regions of the media ( Figure 6D ) and also in the adventitia, especially in the vasa vasorum ( Figure 7) . It is noteworthy that the regions of high GM-CSF expression mainly coincide with the regions of high type VIII collagen expression. However, not all areas showing marked accumulation of type VIII collagen mRNA-expressing cells coincide with strong GM-CSF mRNA expression ( Figure 6D) .
In complicated lesions (types VI, VII, and VIII), a remarkable reduction of the number of expressing cells was observed both in the media and intima. The media was almost devoid of label (not shown). As shown in a type VIII lesion, label in the intima was confined to plaque core structures ( Figure 8A and 8C) . However, the expression of type VIII collagen mRNA remained high ( Figure 8B and 8D) , both in the intima and in the media. GM-CSF and type VIII collagen mRNA were likewise codistributed in clustered cells in the intima. Despite the overall reduction of GM-CSF mRNAexpressing cells, their distribution coincides with regions of high expression of type VIII collagen mRNA.
Mural thrombi are a special feature of the type VI lesions. GM-CSF mRNA ( Figure 9A and 9C) and type VIII collagen mRNA ( Figure 9B and 9D) were both found in organized mural thrombi.
The expression of GM-CSF and type VIII collagen mRNA by EC, SMC, and macrophages was assessed by double-staining in situ hybridization immunohistochemistry. Expressing cell types at different stages of lesion development were identified by using cell type-specific antibodies (Table 2) .
In early lesions, GM-CSF and type VIII collagen mRNA both were expressed in SMC and EC. Macrophages expressing the mRNAs were found only sporadically. In advanced lesions, the number of SMC and macrophages shown to express GM-CSF and type VIII collagen mRNA increased. Nevertheless, EC, SMC, and macrophages that did not express GM-CSF or type VIII collagen mRNA were also common. Some of the GM-CSF and type VIII collagen mRNA-positive cells did not react with any of the cell markers. Such cells were observed in the vessel lumen, attached directly to the endothelium, in the intima, and in the adventitia. They were presumed to represent invading monocytes, granulocytes, T lymphocytes, and adventitial fibroblasts.
GM-CSF Stimulates the Expression of Type VIII Collagen in Vascular SMC
To explore further the possibility whether type VIII collagen mRNA expression can be modulated by GM-CSF, we assessed the expression of type VIII collagen mRNA in GM-CSF-stimulated primary cultures of SMC. We studied the effect of GM-CSF in comparison with several growth factors known to influence the expression of ECM molecules, ie, PDGF, TGF-␤1, and bFGF.
Expression of type VIII collagen mRNA increased (PϽ0.05) after treatment with GM-CSF (1.65-fold, 165.13Ϯ10.64%), PDGF (1.3-fold; 130.7Ϯ8.22%) and TGF-␤1 (1.2-fold; 122.26Ϯ5.19%). Treatment with bFGF did not affect (0.9-fold; 92.5Ϯ8.58%) the transcription of collagen type VIII mRNA ( Figure 10A ). Time-course and dose-response studies on the induction of type VIII collagen mRNA by GM-CSF ( Figure  10B ) demonstrated a maximal response (1.7-to 1.9-fold) at 2 to 4 hours after treatment with 100 pg/mL of the factor.
Discussion
Type VIII collagen is a component of the normal arterial wall. 10 Moreover, its expression is enhanced in response to injury 14 and in atherosclerotic arteries. 15 As we recently demonstrated increasing levels of GM-CSF during atherogenesis, 19 we now studied the relation of GM-CSF to the processes of ECM remodeling occurring during the development of atherosclerotic lesions.
Key findings of the present study are that (1) cultured EC, SMC, and monocytes simultaneously express basal levels of GM-CSF and type VIII collagen mRNA, (2) although cultured macrophages generally express type VIII collagen mRNA, transcription of GM-CSF has to be induced, (3) GM-CSF and type VIII collagen codistribute in apparently nondiseased human arteries and atherosclerotic coronary arteries with lesions of different severity, and (4) GM-CSF transiently stimulates the expression of type VIII collagen mRNA by SMC. Our results provide evidence that GM-CSF, one of the key mediators of inflammation and host defense, is also involved in the process of ECM remodeling during atherogenesis.
Our histological studies demonstrate that in nondiseased arteries and intimal thickenings EC and SMC are the major cell types synthesizing GM-CSF and type VIII collagen. EC are directly exposed to atherogenic factors and blood cells. 34 Stimulation of GM-CSF synthesis by EC after interaction with monocytes has been described recently. 35 Reportedly, GM-CSF is also a potent chemoattractant for monocytes and macrophages. 36 It has been suggested that migration of SMC is related to stimulated expression of type VIII collagen in response to cell mediators and injury. 14,37 Thus, GM-CSF directly attracts cells or might influence their immigration into the intima through its effect on the vascular ECM.
Exactly as described for the response-to-injury model in rat, the early stages of lesion development in humans feature strong expression of type VIII collagen mRNA. At these early stages our data reinforce the observations of Bendeck et al 14 and Sibinga et al 37 in the rat balloon injury model. However, the rather profound expression of type VIII collagen in advanced lesions indicates an additional function. At this stage of lesion development matrix accumulates in the intima 38, 39 but SMC migration has not been suggested as a factor of importance. Thus, deposition of type VIII collagen potentially mediated by GM-CSF may alter the mechanical properties of the intima and contribute to the stability of the lesions.
Type VI to VIII lesions are characterized by an unchanged strong expression of type VIII collagen but a decreased number of GM-CSF-expressing cells, 19 indicating additional factors regulating the expression of type VIII collagen. Noteworthy, codistribution is restricted to macrophage-rich areas. Macrophages are supposed to be responsible for matrix metalloproteinase-mediated destabilization of the plaque cap and thus for plaque rupture, 40 as well as for matrix remodeling via cytokine-dependent mechanisms. 41 Therefore one may speculate that GM-CSF-mediated changes in ECM expression may counterbalance macrophage-induced ECM destabilization. The occurrence of GM-CSF and type VIII collagen in organized thrombi is an additional strong hint that both play a part in tissue organization. A type VIII collagen network may substitute or stabilize matrix structures in a time-restricted manner and, in crosstalk with GM-CSF, promote cell infiltration during thrombus organization.
In vitro EC and SMC simultaneously express basal levels of type VIII collagen and GM-CSF mRNA. Cultured monocytes and macrophages both express type VIII collagen mRNA, although the level markedly decreases during differentiation of monocytes to macrophages. GM-CSF mRNA was markedly expressed in monocytes, but in macrophages only after activation. Thus the synthesis of type VIII collagen and GM-CSF mRNA in cultured monocytes/macrophages is Figure 10 . Expression of ␣1(VIII) collagen mRNA by cultured SMC. A, Northern blot analyses of mRNA levels of ␣1(VIII) collagen mRNA of subconfluent cultures of SMC (start), after preincubation with 0.5% FCS (48h 0.5%), after additional incubation for 4 hours without any factor (4h), and in the presence of various growth factors are demonstrated. Incubation was performed with 50 ng/mL bFGF, 10 pg/mL GM-CSF, 10 ng/mL PDGF-AB, or 5 ng/mL TGF-␤1. Type VIII collagen mRNA expression was stimulated after treatment with GM-CSF, PDGF-AB, and TGF-␤1 (*PϽ0.05). Treatment with bFGF did not influence the transcription of type VIII collagen mRNA. (B) SMC were treated with 1.0 to 500 pg/mL GM-CSF for 35 minutes, 2 hours, 4 hours, and overnight (ON). GM-CSF transiently stimulated the transcription of type VIII collagen. The strongest stimulation of transcription occurred after treatment with 100 pg/mL GM-CSF for 2 to 4 hours. related to their phenotype and, for GM-CSF, depends on the stage of activation. Our finding that GM-CSF transiently stimulates the expression of type VIII collagen mRNA by SMC supports the concept of GM-CSF as a potential regulator of type VIII collagen during the development of atherosclerotic lesions. This effect is even stronger than the stimulation after treatment with PDGF and TGF-␤1, both known to regulate the synthesis of type VIII collagen by SMC. 14, 37 Our studies indicate that GM-CSF and type VIII collagen are critical players during atherogenesis. In addition to the role of GM-CSF as mediator of inflammation and chemoattractant, GM-CSF might be involved in the processes of ECM remodeling. By regulating the synthesis of type VIII collagen in SMC, GM-CSF may influence processes of plaque development, which are related to plaque stability and tissue organization.
